REASONS FOR SITUATION

• Historical Slowness of FDA Review Process

• Cost of Conducting and Submitting Studies for FDA Review

• Liability (e.g., pediatrics)

• Lack of Incentive

Off Patent Drugs

Reimbursement already occurring

Previous slide

Next slide

Back to first slide

View graphic version